SPHK1 and cancer: Due to the frequency with which hyperactivation of the RAS pathway occurs in cancer, constitutive phosphorylation and activation of SPHK1 in cancer is likely to be common, promoting drug resistance by not only depleting ceramide levels but also promoting pro-survival signalling9,15,16.